Bupa backs ban on genetic test use in life insurance
Bupa has backed legislative reform that ensures Australians can access genetic testing without fear that the results could negatively affect their life insurance eligibility.
Our submission to the Senate Economics Legislation Committee welcomes the proposed ban on the use of adverse genetic test results in life insurance underwriting, alongside safeguards that protect consumer autonomy and privacy.
Genomics and pharmacogenomics are rapidly transforming healthcare, offering more personalised, preventive, and effective treatment pathways. Yet many Australians remain hesitant to pursue genetic testing due to concerns about how their data might be used. Strengthening protections in law will give people the confidence to engage with genomic testing helping detect risks earlier, guide safer prescribing, and improve long term health outcomes.
As a leading healthcare organisation, Bupa supports robust safeguards, clear privacy protections, and a regulatory environment that promotes innovation while upholding clinical independence and ethical standards. We are committed to ensuring genomic services remain accessible, safe, and beneficial for all Australians so the shift toward personalised healthcare is both equitable and trusted.
